StreetInsider.com News Articles

DBV Technologies refreshes ATM program with $150M ADS offering

Fri, 17 Jul 2026 17:02:02 -0400

DBV Technologies (Euronext: DBV, NASDAQ: DBVT), a biopharmaceutical company, has filed a shelf registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission to refresh its at-the-market offering program, allowing sales of up to $150 million in American Depositary Shares.

The ATM program was established under a sales agreement dated September 5, 2025, with Citizens JMP Securities, LLC acting as sales agent. Each ADS represents five ordinary shares of the company. The refreshed program carries forward previously registered but unsold ADSs along with newly registered capacity, bringing the total available for issuance and sale to $150 million. The terms

DBV Technologies refreshes ATM program with $150M ADS offering

Fri, 17 Jul 2026 17:02:02 -0400

Cantor Fitzgerald Reiterates Overweight Rating on DBV Technologies S.A (DBVT)

Fri, 17 Jul 2026 09:51:11 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $48.00 price target on DBV Technologies S.A (NASDAQ: DBVT).

The analyst commented, "DBV kicked off 2Q26 earnings for us today (7/16) and hosted a call with updates around VIASKIN (epicutaneous immunotherapy for peanut-allergic children). The core update was that the company announced recruitment has been completed on time in 2Q26 for the COMFORT Toddlers study (recall this is a six-month supplemental safety study to support a filing in 1-3 year olds). The next catalyst for the stock will be submitting the BLA for the 4-7 year olds in 3Q26. The company

DBV Technologies S.A (DBVT) Reiterated at Market Outperform by Citizens on Q2 Pipeline

Fri, 17 Jul 2026 05:11:52 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $55.00 price target on DBV Technologies S.A (NASDAQ: DBVT).

The analyst commented. "DBVT’s pipeline update with 2Q financial results was consistent with its disclosure in late June that the Viaskin Peanut BLA submission in the 4-7 year-old group will be pushed back to 3Q (from 2Q) to incorporate FDA feedback on the application’s organization/formatting. We continue to think it prudent to incorporate the Agency’s feedback, which may minimize the risk of an RTF letter, and potentially accelerate the review process slightly. Management confirmed that enrollment wrapped up last quarter in the

DBV Technologies (DBVT) Misses Q2 EPS by 12c

Thu, 16 Jul 2026 16:20:17 -0400

DBV Technologies (NASDAQ: DBVT) reported Q2 EPS of ($0.12).

For earnings history and earnings-related data on DBV Technologies (DBVT) click here.

DBV Technologies S.A (DBVT) PT Raised to $55 at Citizens

Fri, 01 May 2026 07:18:37 -0400

Citizens analyst Jonathan Wolleben raised the price target on DBV Technologies S.A (NASDAQ: DBVT) to $55.00 (from $47.00) while maintaining a Market Outperform rating.

DBV Technologies (DBVT) Misses Q1 EPS by 11c

Thu, 30 Apr 2026 17:13:59 -0400

DBV Technologies (NASDAQ: DBVT) reported Q1 EPS of ($0.11).

For earnings history and earnings-related data on DBV Technologies (DBVT) click here.

Form 3 DBV Technologies S.A. For: Oct 30 Filed by: Lee Philina

Thu, 16 Apr 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260416/26325752.html

Form 3 DBV Technologies S.A. For: Oct 30 Filed by: Lee Philina

Thu, 16 Apr 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260416/26325752.html

Form 3 DBV Technologies S.A. For: Oct 30 Filed by: Lee Philina

Thu, 16 Apr 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260416/26325752.html

DBV Technologies S.A (DBV:FP) (DBVT) PT Lowered to EUR1.01 at Goldman Sachs

Thu, 09 Apr 2026 07:51:29 -0400

Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating.

DBV Technologies S.A (DBV:FP) (DBVT) PT Lowered to EUR1.01 at Goldman Sachs

Thu, 09 Apr 2026 07:51:29 -0400

Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating.

DBV Technologies S.A (DBV:FP) (DBVT) PT Lowered to EUR1.01 at Goldman Sachs

Thu, 09 Apr 2026 07:51:29 -0400

Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating.

DBV Technologies S.A (DBV:FP) (DBVT) PT Lowered to EUR1.01 at Goldman Sachs

Thu, 09 Apr 2026 07:51:29 -0400

Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating.

DBV Technologies S.A (DBVT) PT Lowered to $5.81 at Goldman Sachs

Thu, 09 Apr 2026 05:56:55 -0400

Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (NASDAQ: DBVT) to $5.81 (from $7.94) while maintaining a Sell rating.

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Thu, 02 Apr 2026 16:30:00 -0400

Information Regarding the Total Number of Voting Rights and
Total Number of Shares of the Company as of March 31, 2026